Anavex Life Sciences Corp.AVXLNASDAQ
Loading
SG&A Expense Growth AcceleratingAccelerating
Percentile Rank71
3Y CAGR-17.6%
Year-over-Year Change
Year-over-year SG&A expense growth
3Y CAGR
-17.6%/yr
vs +23.1%/yr prior
Acceleration
-40.7pp
Decelerating
Percentile
P71
Within normal range
vs 3Y Ago
0.6x
Contraction
Streak
1 yr
Consecutive growthAccelerating
| Period | Value |
|---|---|
| 2025 | 25.16% |
| 2024 | -8.36% |
| 2023 | -7.83% |
| 2022 | 44.93% |
| 2021 | 53.98% |
| 2020 | -14.46% |
| 2019 | 14.32% |
| 2018 | 19.59% |
| 2017 | -39.91% |
| 2016 | 72.31% |